Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MacroGenics Inc

MGNX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.25

▼ -1.62%

Market Cap $270.73M · Vol 181.64K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$270.73M

Micro Cap

Div Yield

N/A

EPS Growth

+11.86%

YoY

RSI (14)

51.08

Momentum

Beta

1.19

vs Market

52W High

$5.08

14.88% below

52W Low

$1.30

233.59% above

Volume

181.64K

Avg 192.38K

P/B

1.83

Price-to-book

ROE

N/A

Return on equity

Free Float

96.41%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, MacroGenics Inc (MGNX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MGNX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.17%

+11.26%

+1.19%

+123.68%

YTD

+163.98%

+122.51%

-12.55%

-81.11%

Financials & Valuation

TTM · Annual

Total Revenue	$149.50M
Net Income	$-74,620,000.00
Revenue Growth (YoY)	+377.97%
Gross Margin	75.91%
Operating Margin	-48.72%
Net Profit Margin	-49.91%
ROE	N/A
ROA · ROIC	-29.04% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.68
P/B	1.83
P/FCF	N/A
EPS Growth	+11.86%
Outstanding Shares	63.70M

Technical Indicators

50-Day SMA	$4.21
200-Day SMA	$3.01
RSI (14)	51.08
Beta	1.19
52-Week High	$5.08
52-Week Low	$1.30

Volume Today	181.64K
Avg Daily Volume (30D)	192.38K
Relative Volume	0.94x
Volatility (10D)	47.29
Volatility (30D)	54.34
Free Float	96.41%

Analyst Consensus

BUY

Current Price $4.25

Mean Target $9.33

52W Low$1.30 52W High$5.08

Current

Target

$1.30 $5.08

Current Analyst target

+119.61% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S9C8R7

ISINUS5560991094

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.77% ARGX.BR argenx SE +1.31% ARGX argenx SE -0.18% INSM Insmed Inc +0.04% 2269.HK WuXi Biologics (Cayman) Inc +2.97%

Company Profile

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.